A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer
E. Casado(Hospital Universitario La Paz), Paloma Cejas(Dana-Farber Cancer Institute), Damián García‐Olmo(Hospital Universitario Fundación Jiménez Díaz), Rosa Miquel(Hospital Universitario La Paz), Cristóbal Belda-Iniesta(Instituto de Salud Carlos III), Joan Maurel(Breast Cancer Research Foundation), María Sereno(Hospital Universitario Infanta Sofía), Noemí Manceñido(Hospital Universitario La Paz), Benito Sánchez-Llamas(Hospital Universitario La Paz), Carlos Fernández-Martos(Fundación Instituto Valenciano de Oncología), Miguel Ángel García‐Cabezas(Boston University), Beatriz Castelo, Montserrat Blanco(Hospital Universitario La Paz), Manuel González-Barón(Hospital Universitario La Paz), José Javier Sánchez(Research Institute Hospital 12 de Octubre), Jaime Feliú(Hospital Universitario La Paz), Emilio Burgos(Hospital Universitario Infanta Sofía), Víctor Moreno
Cited by 32
Related Papers
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
|Cancer Discovery|2021|286